|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 161 N. Clark |
Address2 | Suite 3550 |
City | Chicago |
State | IL |
Zip Code | 60601 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 400348610-12
|
||||||||
|
6. House ID# 403510000
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Paul Melmeyer |
Date | 1/24/2023 2:53:03 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Health care issues affecting individuals with neuromuscular disease including therapy development, newborn screening, screening and diagnosis, adequate insurance coverage, and access to care.
Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 482 / S. 350, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients.
Advocated for robust funding of the national newborn screening program.
Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, Centers for Disease Control and Prevention, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions.
Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions.
Advocated for the swift funding and implementation of the ACT for ALS Act (S.1813 and H.R.3537).
Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency.
Advocated for increased funding of home and community-based services (HCBS).
Supported the passage of the e Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R. 5030/S. 2706)
Advocated for reforms to the FDA Accelerated Approval program as part of the end-of-year omnibus package.
Advocated for the creation of an FDA regulatory pathway for diagnostics, including lab-developed tests and invitro diagnostics.
Supported greater appropriations for Consumer Assistance Programs
Advocated for the passage of the RARE Act (S. 4185) as part of the end-of-year omnibus package.
Supported passage of the Ending the Diagnostic Odyssey Act
Advocated for the passage of the Accelerating Kids Access to Care Act
Advocated for certain provisions within the Cures 2.0 Legislation (H.R.6000)
Support the passage of the Precision Medicine for Children Act
Advocated for the passage of the HCBS Access Act
Supported the passage of the Stop the Wait Act (S. 3575 / H.R. 6583)
Advocated for the Access to Genetic Counselors Act
Provided recommendations to the Department of Health and Human Services on the implementation of section 1557 of the Affordable Care Act.
Applauded the Department of Health and Human Services in their closing of the family glitch within the Affordable Care Act.
Advocated to the Centers for Medicare and Medicaid Services on Medicaid access and the COVID-19 public health emergency
Called for passage of the Preserving Patient Access to Home Infusion Act (S. 2652/H.R. 5067)
Provided comments to CMS on ensuring equity in accessing health care.
Provided comments to the Department of Health and Human Services on how best to streamline eligibility and enrollment within the Medicaid and CHIP programs.
Called for recipients of the Deferred Action for Childhood Arrivals program to access Federal health programs and offerings.
Provided comments to the CMS on the implementation of the No Surprises Act.
Called for greater funding of the National Center for Advancing Translational Sciences (NCATS)
Called for the passage of the Medicare Orthotic & Prosthetic Patient-Centered Care Act
Provided comments to CMS on National Directory of Healthcare Providers and Services
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Treasury - Dept of, Labor - Dept of (DOL), Health Resources & Services Administration (HRSA), Natl Council on Disability
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Michael |
Lewis |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AVI
16. Specific lobbying issues
Advocated for the passage of the Air Carrier Access Amendments Act (S.642, H.R.1893)
Advocated for further air travel access improvements for individuals with disabilities through regulation by FAA and DoT.
Advocated for further accessible air travel reforms within the 2023 FAA reauthorization.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Federal Aviation Administration (FAA), Transportation - Dept of (DOT)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Michael |
Lewis |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Advocated for robust funding for the Newborn Screening programs at the CDC, NIH, and HRSA
Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, Centers for Disease Control and Prevention, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions.
Advocated for increased funding of the National Center for Advancing Translational Sciences (NCATS)
Advocated for the swift funding and implementation of the ACT for ALS Act (S.1813 and H.R.3537).
Advocated for increased funding of home and community-based services (HCBS).
Advocated for greater funding amounts going towards Department of Education programs focused on educational offerings for those with disabilities.
Advocated for additional funding for the Social Security Administration to implement programs for those with disabilities
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Food & Drug Administration (FDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Education - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Michael |
Lewis |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Advocated in favor of robust appropriations funding for the National Institutes of Health, the Food and Drug Administration, the Health Resources and Services Administration, and the Centers for Disease Control and Prevention.
Advocated for greater appropriations for the National Center for Advancing Translational Sciences (NCATS)
Advocated for greater appropriations for the National Institutes of Health.
Advocated for appropriations for HHS, NIH, and FDA to implement the ACT for ALS.
Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 482 / S. 350, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients.
Supported the passage of the e Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R. 5030/S. 2706)
Advocated for reforms to the FDA Accelerated Approval program as part of the end-of-year omnibus legislation.
Advocated for the creation of an FDA regulatory pathway for diagnostics, including lab-developed tests and invitro diagnostics.
Advocated for the passage of the RARE Act (S. 4185) as part of the Senate FDA User Fee process.
Advocated for certain provisions within the Cures 2.0 Legislation (H.R.6000)
Advocated for passage of FDA and clinical trial reforms within an end-of-year bill, including accelerated approval reforms, clinical trial diversity advancements, the RARE Act, reauthorization of the Orphan Product Grants Program, and more.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions.
Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency.
Supported passage of the Ending the Diagnostic Odyssey Act
Advocated for the passage of the Accelerating Kids Access to Care Act
Advocated for certain provisions within the Cures 2.0 Legislation (H.R.6000)
Support the passage of the Precision Medicine for Children Act
Advocated for the passage of the HCBS Access Act
Advocated for the Access to Genetic Counselors Act
Called for the passage of the Medicare Orthotic & Prosthetic Patient-Centered Care Act
Provided comments to the Department of Health and Human Services on how best to streamline eligibility and enrollment within the Medicaid and CHIP programs.
Advocated to the Centers for Medicare and Medicaid Services on Medicaid access and the COVID-19 public health emergency
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions.
Advocated for access to healthcare via telemedicine/telehealth throughout and after the COVID-19 public health emergency.
Advocated for certain provisions within the Cures 2.0 Legislation (H.R.6000)
Supported passage of the Ending the Diagnostic Odyssey Act
Provided comments to CMS on National Directory of Healthcare Providers and Services
Provided comments to the CMS on the implementation of the No Surprises Act.
Called for passage of the Preserving Patient Access to Home Infusion Act (S. 2652/H.R. 5067)
Applauded the Department of Health and Human Services in their closing of the family glitch within the Affordable Care Act.
Provided recommendations to the Department of Health and Human Services on the implementation of section 1557 of the Affordable Care Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
Advocated for the Transformation to Competitive Integrated Employment Act (H.R.2373 and S.3238)
Advocated for the passage of the Disability Employment Incentive Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Michael |
Lewis |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Advocated for funding and implementation of the ACT for ALS, a law that should accelerate development of treatments for individuals with ALS and other neuromuscular diseases.
Advocated for the passage of the Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R. 5030/S. 2706)
Supported passage of the Ending the Diagnostic Odyssey Act
Advocated for the passage of the Accelerating Kids Access to Care Act
Advocated for certain provisions within the Cures 2.0 Legislation (H.R.6000)
Support the passage of the Precision Medicine for Children Act
Advocated for reforms to the FDA Accelerated Approval program as part of the end-of-year omnibus package
Advocated for the creation of an FDA regulatory pathway for diagnostics, including lab-developed tests and invitro diagnostics.
Advocated for passage of FDA and clinical trial reforms within an end-of-year bill, including accelerated approval reforms, clinical trial diversity advancements, the RARE Act, reauthorization of the Orphan Product Grants Program, and more.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Supported the Disability Employment Incentive Act, legislation that doubles incentives for businesses to hire individuals with disabilities.
Advocated for the passage of the SSI Savings Penalty Elimination Act (S. 4102)
Advocated for the enactment of the ABLE Age Adjustment Act
Advocated for the passage of the Supplemental Security Income Restoration Act (S. 2065 / HR 3763)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Treasury - Dept of, Social Security Administration (SSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Michael |
Lewis |
|
|
|
Joel |
Cartner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRA
16. Specific lobbying issues
Advocated for the passage of the Air Carrier Access Amendments Act (S.642, H.R.1893)
Advocated for further air travel access improvements for individuals with disabilities through regulation by FAA and DoT.
Advocated for accessible air travel priorities to be included in the 2023 FAA reauthorization.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, Federal Aviation Administration (FAA), U.S. HOUSE OF REPRESENTATIVES, Transportation - Dept of (DOT)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Melmeyer |
|
|
|
Joel |
Cartner |
|
|
|
Michael |
Lewis |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code EDU
16. Specific lobbying issues
Advocated for greater funding amounts going towards Department of Education programs focused on educational offerings for those with disabilities.
17. House(s) of Congress and Federal agencies Check if None
Education - Dept of, U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Lewis |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |